Hamburg, Germany, 19 October 2020:
Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a € 22 m (~US$ 26 m) Series B financing round. New investors Vesalius BioCapital III and BioMedPartners co-led this transaction, which included participation from all of Topas' existing investors. The funding will be used to advance the Company's proprietary pipeline based on the Topas Particle Conjugates technology platform.
In a separate release the company announced the appointment of Klaus Martin, Ph.D., as Chief Executive Officer. Effective August 1, 2020, Dr. Martin replaced Timm Jessen, Ph.D., who resigned for personal reasons. Dr. Jessen will remain with Topas in a consulting capacity to ensure a smooth transition.
For further information, please follow this link to Topas Therapeutics' press releases.